Daiichi Sankyo plans to invest approximately EUR 1 billion ($1.1 billion) to expand its production and development site in Pfaffenhofen an der Ilm, Germany (north of Munich) into an international innovation center. The expansion of the plant has already begun and is expected to be completed by 2030 at the latest.  

At least 350 new jobs will be created by 2030, including numerous positions for researchers, process engineers, and other specialists in sterile manufacturing and biotechnology. Production capacity will be added to support cardiovascular drugs, and new laboratories will be established for antibody drug conjugates (ADCs). The new building for Daiichi Sankyo’s ADCs is expected to be completed by the end of 2026. In the future, cancer therapies for breast, lung, and stomach cancer, among other cancer drugs, will be developed and manufactured in Pfaffenhofen. 

Source: Daiichi Sankyo